Real-World Effectiveness of Eptinezumab after Treatment with Subcutaneous CGRP Monoclonal Antibodies in Patients with Migraine

被引：0
|
作者：
Casaletto, Emily [1 ]
Yang, Qiu Zi [1 ]
Waters, John [1 ]
Curran, John [1 ]
Lowe, Austin [1 ]
Yuan, Hsiangkuo [1 ]
机构：
[1] Thomas Jefferson Univ, Dept Neurol, Philadelphia, PA USA
来源：
NEUROLOGY | 2023年 / 100卷 / 17期
关键词：
D O I：
10.1212/WNL.0000000000203712
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P12-12.009
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Safety and tolerability of anti-CGRP monoclonal antibodies: a real-world study
    Corral-Quereda, C.
    Sanchez-Casado, L.
    Diaz-de-Teran, J.
    Sastre-Real, M.
    JOURNAL OF HEADACHE AND PAIN, 2021, 22 (SUPPL 1): : 120 - 121
  • [32] Resumption of migraine preventive treatment with CGRP(-receptor) antibodies after a 3-month drug holiday: a real-world experience
    Bianca Raffaelli
    Maria Terhart
    Jasper Mecklenburg
    Lars Neeb
    Lucas Hendrik Overeem
    Anke Siebert
    Maureen Steinicke
    Uwe Reuter
    The Journal of Headache and Pain, 2022, 23
  • [33] Resumption of migraine preventive treatment with CGRP(-receptor) antibodies after a 3-month drug holiday: a real-world experience
    Raffaelli, Bianca
    Terhart, Maria
    Mecklenburg, Jasper
    Neeb, Lars
    Overeem, Lucas Hendrik
    Siebert, Anke
    Steinicke, Maureen
    Reuter, Uwe
    JOURNAL OF HEADACHE AND PAIN, 2022, 23 (01):
  • [34] Real world experience after one year of treatment with antiCGRP monoclonal antibodies in patients with chronic migraine
    Gonzalez-Quintanilla, V.
    Madera Fernandez, J.
    Garate, G.
    Perez-Pereda, S.
    Pascual Gomez, J.
    JOURNAL OF HEADACHE AND PAIN, 2024, 25
  • [35] REAL-WORLD EVIDENCE FOR CONTROL OF PATIENTS WITH CHRONIC MIGRAINE WHO RECEIVED CGRP MONOCLONAL ANTIBODY THERAPY ADDED TO ONABOTULINUMTOXINA TREATMENT
    Blumenfeld, Andrew M.
    Frishberg, Benjamin M.
    Schim, Jack D.
    Iannone, Ashley
    Schneider, Gary
    Yedigarova, Larisa
    Adams, Aubrey Manack
    CEPHALALGIA, 2020, 40 : 96 - 97
  • [36] Safety and tolerability of anti-CGRP monoclonal antibodies: a real-world study
    Corral-Quereda, C.
    Sanchez-Casado, L.
    Diaz-de-Teran, J.
    Sastre-Real, M.
    CEPHALALGIA, 2021, 41 (1_SUPPL) : 179 - 179
  • [37] Methodological considerations on real-world evidence studies of monoclonal antibodies against the CGRP-pathway for migraine: a systematic review
    Vandenbussche, Nicolas
    Pisarek, Karolina
    Paemeleire, Koen
    JOURNAL OF HEADACHE AND PAIN, 2023, 24 (01):
  • [38] Effectiveness of anti-CGRP monoclonal antibodies in the preventive treatment of migraine: A prospective study of 63 patients
    Castrillo, Ana
    Mendoza, Amelia
    Caballero, Lorena
    Cerdan, Debora
    Rodriguez, Maria Fernanda
    Guerrero, Pilar
    Tabernero, Cesar
    Ferrero, Marta
    Benito, Ines
    Marin, Laura
    Duarte, Jacinto
    MEDICINA CLINICA, 2023, 160 (08): : 341 - 346
  • [39] Methodological considerations on real-world evidence studies of monoclonal antibodies against the CGRP-pathway for migraine: a systematic review
    Nicolas Vandenbussche
    Karolina Pisarek
    Koen Paemeleire
    The Journal of Headache and Pain, 24
  • [40] Comparative effectiveness and tolerability of calcitonin gene-related peptide (CGRP) monoclonal antibodies and onabotulinumtoxinA in chronic migraine: A multicenter, real-world study in Taiwan
    Wang, Yen-Feng
    Yang, Fu-Chi
    Chen, Lu-An
    Chang, Ting-Yu
    Su, Hui-Chen
    Yang, Chun-Pai
    Tu, Yi-Hsien
    Tzeng, Yi-Shiang
    Chen, Shih-Pin
    Fuh, Jong-Ling
    Lai, Kuan-Lin
    Ling, Yu-Hsiang
    Chen, Wei-Ta
    Wang, Shuu-Jiun
    EUROPEAN JOURNAL OF NEUROLOGY, 2024, 31 (09)
12345